Oral #enlicitide lowered LDL-C, #ApoB, & non-HDL-C more than oral non-statin comparators at day 56 in statin-treated adults with a history of a major #ASCVD event or at increased risk for a first event. https://bit.ly/47Ao7hw

#ACC26 #JACC #PCSK9i #CardioSky

American Diabetes Association American Diabetes Association

FOURIER data on the benefit of #PCSK9i #evolocumab in adults with #T1D are now cited in the 2026 @AmDiabetesAssn
Standards of Care—an important step in an area w/ very limited evidence to guide intensive #LDL-C lowering in T1D.

diabetesjournals.org/care/article...

❤️In ASCVD patients high‑intensity LDL lowering cuts #Lp(a) linked risk & PCSK9i add extra benefit
No significant interaction suggests #PCSK9i deliver consistent risk ⬇️regardless of baseline Lp(a)

tinyurl.com/5eb97nmb

@eassociety.bsky.social #EHJ #EAS
#BorgeNordestgaard #DianeMacDougall

At #ACC25, Dr. Michael J. Koren & colleagues present the results of PURSUIT, which found that a novel oral #PCSK9i achieved LDL reductions on top of background statin therapy with a similar side effect profile to placebo jacc.org/doi/10.1016/... #JACC

Exciting new development in lipid field! The early Phase 2 #PURSUIT trial showed a novel oral #PCSK9i (that can be taken with food) lowered LDL-C by 51% at 12 weeks. 84% achieved LDL-C of <70 mg/dL. #ACC25 @accintouch.bsky.social

Very short-term effects of a single dose of a proprotein convertase subtilisin/kexin 9 inhibitor before percutaneous coronary intervention: A single-arm study The short-term (within 6 weeks) effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on lipid plaques have not been adequately evaluated. We aimed to investigate whether a single dos...

'A single dose of PCSK9 inhibitor reduced lipid-core plaque abundance before coronary intervention.

Evolocumab lowered LDL-C, Lp(a), and MDA-LDL levels within a short period.'
#PCSK9i repatha #cardiosky #CvPrev
www.atherosclerosis-journal.com/article/S002...